Alonso Ricardo, PhD

Venture Partner

Alonso Ricardo is a Venture Partner at Raven. Prior to Raven, Alonso co-founded and was the former Chief Scientific Officer of Mariana Oncology, an RA Capital portfolio company focused on the development of targeted therapies for the treatment of solid tumors (acquired by Novartis). Before Mariana Oncology, Alonso was an entrepreneur-in-residence at RA Capital and the Chief Technology and Innovation Officer at Ra Pharmaceuticals (acquired by UCB). Alonso has experience leading scientific programs across multiple therapeutic programs in immunology, metabolic diseases, and oncology. Alonso led the discovery and early development of ZILBRYSQ®, a first-in-class immune modulator peptide drug approved for the treatment of generalized myasthenia gravis, the discovery of an orally available peptide targeting PCSK9 (MK-0616) in development by Merck for the treatment of hypercholesterolemia, and the discovery of radiotheranostic peptides for the treatment of a variety of solid tumors. Alonso was formerly a professor at the Universidad de los Andes in Bogota, Colombia, and a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. Alonso holds a PhD in Chemistry from the University of Florida and was a postdoctoral fellow at the Foundation for Applied Molecular Evolution.